ID   OVCA429
AC   CVCL_3936
SY   OVCA 429; OvCA 429; OVCA-429; OVCAR-429; OVCAR 429; OVCAR429; OV429
DR   BTO; BTO:0002564
DR   EFO; EFO_0006721
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03470937
DR   cancercelllines; CVCL_3936
DR   Cosmic; 924146
DR   Cosmic; 927567
DR   Cosmic; 1223315
DR   Cosmic; 1328064
DR   Cosmic; 1434898
DR   Cosmic; 2074245
DR   EGA; EGAS00001000610
DR   GEO; GSM95439
DR   GEO; GSM659391
DR   GEO; GSM711704
DR   GEO; GSM851929
DR   IARC_TP53; 28487
DR   PharmacoDB; OvCA429_1214_2019
DR   Progenetix; CVCL_3936
DR   Wikidata; Q54936983
RX   PubMed=1536252;
RX   PubMed=6346879;
RX   PubMed=7028788;
RX   PubMed=10318951;
RX   PubMed=10972993;
RX   PubMed=12080474;
RX   PubMed=12960427;
RX   PubMed=16380993;
RX   PubMed=16382445;
RX   PubMed=19926575;
RX   PubMed=20204287;
RX   PubMed=20596667;
RX   PubMed=22710073;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=30485824;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 34.58 hours (JWGray panel).
CC   HLA typing: A*26:01,26:01; B*39:01,39:01; C*12:03,12:03 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (PubMed=20204287).
CC   Omics: Array-based CGH.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): PubMed=20596667; PubMed=22710073; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 12,13 (PubMed=20596667; PubMed=22710073; PubMed=25877200)
ST   CSF1PO: 12,13,14 (PubMed=30485824)
ST   D13S317: 7,12 (PubMed=22710073; PubMed=25877200; PubMed=30485824)
ST   D13S317: 12 (PubMed=20596667)
ST   D16S539: 12
ST   D18S51: 14
ST   D19S433: 13
ST   D21S11: 30
ST   D2S1338: 19,20
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   D8S1179: 14,15
ST   FGA: 24
ST   Penta D: 13,14
ST   Penta E: 12
ST   TH01: 9
ST   TPOX: 9,11
ST   vWA: 16,18
DI   NCIt; C5228; Ovarian cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 28
//
RX   PubMed=1536252; DOI=10.1016/0002-9378(92)91697-9;
RA   Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P.,
RA   Arrick B.A., Clarke-Pearson D.L., Bast R.C. Jr.;
RT   "Regulation of growth of normal ovarian epithelial cells and ovarian
RT   cancer cell lines by transforming growth factor-beta.";
RL   Am. J. Obstet. Gynecol. 166:676-684(1992).
//
RX   PubMed=6346879; DOI=10.1016/0002-9378(83)90999-7;
RA   Berkowitz R.S., Kabawat S., Lazarus H., Colvin R.B., Knapp R.C.,
RA   Bast R.C. Jr.;
RT   "Comparison of a rabbit heteroantiserum and a murine monoclonal
RT   antibody raised against a human epithelial ovarian carcinoma cell
RT   line.";
RL   Am. J. Obstet. Gynecol. 146:607-612(1983).
//
RX   PubMed=7028788; DOI=10.1172/JCI110380; PMCID=PMC370929;
RA   Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B.,
RA   Knapp R.C.;
RT   "Reactivity of a monoclonal antibody with human ovarian carcinoma.";
RL   J. Clin. Invest. 68:1331-1337(1981).
//
RX   PubMed=10318951; DOI=10.1073/pnas.96.10.5722; PMCID=PMC21927;
RA   Lau K.-M., Mok S.C., Ho S.-M.;
RT   "Expression of human estrogen receptor-alpha and -beta, progesterone
RT   receptor, and androgen receptor mRNA in normal and malignant ovarian
RT   epithelial cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999).
//
RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;
RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;
RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon
RT   12 deletion variant in malignant human ovarian, prostate, and breast
RT   cancer cell lines.";
RL   Mol. Carcinog. 28:236-246(2000).
//
RX   PubMed=12080474; DOI=10.1038/sj.onc.1205542;
RA   Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I.,
RA   Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.B.,
RA   Auersperg N., Birrer M.J.;
RT   "CL100 expression is down-regulated in advanced epithelial ovarian
RT   cancer and its re-expression decreases its malignant potential.";
RL   Oncogene 21:4435-4447(2002).
//
RX   PubMed=12960427; DOI=10.1091/mbc.E03-05-0279; PMCID=PMC266758;
RA   Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G.,
RA   Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H.,
RA   Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J.,
RA   Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R.,
RA   van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O.,
RA   Sikic B.I.;
RT   "Gene expression patterns in ovarian carcinomas.";
RL   Mol. Biol. Cell 14:4376-4386(2003).
//
RX   PubMed=16380993; DOI=10.1002/ijc.21671;
RA   Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X.-Y., Ng W.-C.,
RA   Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.;
RT   "Selenium binding protein 1 in ovarian cancer.";
RL   Int. J. Cancer 118:2433-2440(2006).
//
RX   PubMed=16382445; DOI=10.1002/gcc.20300;
RA   Wang Y.C., Juric D., Francisco B., Yu R.X., Duran G.E., Chen G.K.,
RA   Chen X., Sikic B.I.;
RT   "Regional activation of chromosomal arm 7q with and without gene
RT   amplification in taxane-selected human ovarian cancer cell lines.";
RL   Genes Chromosomes Cancer 45:365-374(2006).
//
RX   PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS; PMCID=PMC3040237;
RA   DeRycke M.S., Andersen J.D., Harrington K.M., Pambuccian S.E.,
RA   Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.;
RT   "S100A1 expression in ovarian and endometrial endometrioid carcinomas
RT   is a prognostic indicator of relapse-free survival.";
RL   Am. J. Clin. Pathol. 132:846-856(2009).
//
RX   PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445;
RA   Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H.,
RA   Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.;
RT   "Radiosensitivity profiles from a panel of ovarian cancer cell lines
RT   exhibiting genetic alterations in p53 and disparate DNA-dependent
RT   protein kinase activities.";
RL   Oncol. Rep. 23:1021-1026(2010).
//
RX   PubMed=20596667; DOI=10.3892/ijo_00000688;
RA   Chay D.B., Cho H., Lim B.J., Kang E.S., Oh Y.J., Choi S.M., Kim B.W.,
RA   Kim Y.T., Kim J.-H.;
RT   "ER-60 (PDIA3) is highly expressed in a newly established serous
RT   ovarian cancer cell line, YDOV-139.";
RL   Int. J. Oncol. 37:399-412(2010).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//